A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS)
Year: 2017
Type: conference-abstract
Source: European Urology Supplements
Authors: M. Smith, F. Saad, M. Hussain, C. Sternberg, K. Fizazi, D. Crawford, K. Yamada, C. Kappeler, I. Kuss, B. Tombal
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2600996424